Products
CDM Insights®
FDA cleared post-processing MRI image analysis tool
Unlocking the power of microstructure. CDM Insights® provides a window into the size and composition of a patient's brain.
Going beyond standard measures like volume and atrophy
Our proprietary technology sheds light on the changes happening in the gray matter like never before.
Combining macrostructural and microstructural information about the cerebral cortex, CDM Insights® also provides additional metrics, including White Matter Hyper/Hypointensities.
We hope this new report will support Neurologists, Radiologists and Neuroradiologists around the world in their efforts to diagnose early, provide treatment and support for patients and carers.
Non Invasive, longitudinal tracking and detailed insights
Per patient, our report will provide Whole Brain and Regional measurements with the ability to track changes across multiple time points.
CDM Insights® will deliver details at the microstructural level and broader quantitative information at the macrostructural scale, combined in the same report.
Download a sample report to view
Safe, secure and cloud based
CDM Insights® uses standard structural MRI scan data (including diffusion) that is submitted via hospital PACS for processing in the cloud. Oxford Brain Diagnostics is ISO13485 certified. We are GDPR and HIPAA compliant regarding data privacy rules.
We are ready to work with your Hospital PACs integrators and deliver our reports securely.
Within 36 hours of scan upload, the clincians will have access to CDM Insights® for that patient.
Send us a scan and test us
Pharma/Biotech
Better drug development
Previously inaccessible insights, unlocked by our proprietary CDM technology, will enable more targeted, efficient drug development.
Select AD
Using CDM® we will optimise patient selection, combine other clinical and patient demographics, and positively impact trial costs and performance. CDM® can estimate a patient’s pathology disease stage using grey matter quality. We provide a likelihood that a patient will progress to the next stage of disease within the next few years.
Track AD
We can provide longitudinal patient results based on changes across baseline and time points in accordance with your clinical trial protocol. Grey matter quality changes can also be provided in brain visualisations over multiple time periods. We can provide our results based on whole brain, brain regions and even sub regions if required.
